ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial
Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determin...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2008-09, Vol.118 (13), p.1335-1346 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1346 |
|---|---|
| container_issue | 13 |
| container_start_page | 1335 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 118 |
| creator | BULLER, Christopher E YULING FU GRANGER, Christopher B ARMSTRONG, Paul W MAHAFFEY, Kenneth W TODARO, Thomas G ADAMS, Péter WESTERHOUT, Cynthia M WHITE, Harvey D VAN 'T HOF, Arnoud W. J VAN DE WERF, Frans J WAGNER, Galen S |
| description | Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction.
We analyzed ECG data describing the magnitude and extent of ST-segment elevation and deviation before and early after (ie, 30 minutes) primary PCI in the study cohort of 4866 subjects with electrocardiographically high-risk ST-elevation myocardial infarction enrolled in the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Associations among 6 methods for calculating ST-segment recovery, biomarker estimates of infarct size (ie, peak creatine kinase, creatine kinase-MB, and troponin I and T), and prespecified clinical outcomes (ie, rates of 90-day death and 90-day death, heart failure, or shock) were examined. All ST-segment-recovery methods provided strong prognostic information regarding clinical outcomes. A simple ST-segment-recovery method of residual ST-segment elevation measurement in the most affected lead on the post-PCI ECG performed as well as complex methods that required comparison of pre- and post-PCI ECGs or calculation of summed ST-segment deviation in multiple leads (ie, worst-lead residual ST elevation: adjusted hazard ratio for 90-day death rate [reference |
| doi_str_mv | 10.1161/CIRCULATIONAHA.108.767772 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69589481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69589481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-ae8f0911907bacd33e0a8af42bc9c8ac7fef8421659dab44ff912b97887a25463</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EotvCKyBzAMEhS-w4sc0tirY00pZdtVuJW-Q44zYoiYudrFrek_fB3axAHDhZ888381vzI_SWxEtCMvKpKK-Km3W-Kzdf84t8SWKx5BnnnD5DC5JSFrE0kc_RIo5jGfGE0hN06v33UGYJT1-iEyI4l4yxBfp1vYuu4baHYcRXoO0e3CNWQ4M306htDzg3Izi8dW2vQmcLTk-jGsBOHhfW2eFJLYfA7MOK1g7YWIfD0lUHe3UQLh-tVq5pVRdAo5w-qJ9D4dvbu9Hjc2d7PN4FL-_B-8NfrAleD9C1P6de1bgdcB6M4T_LPuTb1bcovyw_4p0LvVfohVGdh9fH9wzdnK92xUW03nwpi3wd6SShY6RAmFgSImNeK90kCcRKKMNoraUWSnMDRjBKslQ2qmbMGEloLbkQXNGUZckZej_vvXf2xwR-rPrWa-i6-UJVJlMhmSABlDOonfXeganu54tWJK6eMq3-zTTIopozDbNvjiZT3UPzd_IYYgDeHQHlteqMU4Nu_R-OxpkkkmTJb5KssBk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69589481</pqid></control><display><type>article</type><title>ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB Electronic Journals Library</source><source>Journals@Ovid Complete</source><creator>BULLER, Christopher E ; YULING FU ; GRANGER, Christopher B ; ARMSTRONG, Paul W ; MAHAFFEY, Kenneth W ; TODARO, Thomas G ; ADAMS, Péter ; WESTERHOUT, Cynthia M ; WHITE, Harvey D ; VAN 'T HOF, Arnoud W. J ; VAN DE WERF, Frans J ; WAGNER, Galen S</creator><creatorcontrib>BULLER, Christopher E ; YULING FU ; GRANGER, Christopher B ; ARMSTRONG, Paul W ; MAHAFFEY, Kenneth W ; TODARO, Thomas G ; ADAMS, Péter ; WESTERHOUT, Cynthia M ; WHITE, Harvey D ; VAN 'T HOF, Arnoud W. J ; VAN DE WERF, Frans J ; WAGNER, Galen S</creatorcontrib><description>Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction.
We analyzed ECG data describing the magnitude and extent of ST-segment elevation and deviation before and early after (ie, 30 minutes) primary PCI in the study cohort of 4866 subjects with electrocardiographically high-risk ST-elevation myocardial infarction enrolled in the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Associations among 6 methods for calculating ST-segment recovery, biomarker estimates of infarct size (ie, peak creatine kinase, creatine kinase-MB, and troponin I and T), and prespecified clinical outcomes (ie, rates of 90-day death and 90-day death, heart failure, or shock) were examined. All ST-segment-recovery methods provided strong prognostic information regarding clinical outcomes. A simple ST-segment-recovery method of residual ST-segment elevation measurement in the most affected lead on the post-PCI ECG performed as well as complex methods that required comparison of pre- and post-PCI ECGs or calculation of summed ST-segment deviation in multiple leads (ie, worst-lead residual ST elevation: adjusted hazard ratio for 90-day death rate [reference <1 mm]: 1 to <2 mm, 1.23 [95% CI 0.74 to 2.03]; > or =2 mm, 2.22 [95% CI 1.35 to 3.65], corrected c-index=0.832; 90-day death/congestive heart failure/shock [reference <1 mm]: 1 to <2 mm, 1.55 [95% CI 1.06 to 2.26]; > or =2 mm, 2.33 [95% CI 1.59 to 3.41], corrected c-index=0.802). Biomarker estimates of infarct size declined in association with enhanced ST-segment recovery.
An ECG performed early after primary PCI is a simple, widely available, inexpensive, and powerful prognostic tool applicable to patients with ST-elevation myocardial infarction.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.108.767772</identifier><identifier>PMID: 18779444</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Angioplasty, Balloon, Coronary - mortality ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cohort Studies ; Combined Modality Therapy ; Coronary heart disease ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Electrocardiography ; Female ; Heart ; Heart Failure - mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Myocardial Infarction - diagnosis ; Myocardial Infarction - mortality ; Myocardial Infarction - therapy ; Predictive Value of Tests ; Prognosis ; Recovery of Function ; Shock, Cardiogenic - mortality ; Single-Chain Antibodies ; Treatment Outcome</subject><ispartof>Circulation (New York, N.Y.), 2008-09, Vol.118 (13), p.1335-1346</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c332t-ae8f0911907bacd33e0a8af42bc9c8ac7fef8421659dab44ff912b97887a25463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3688,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20691916$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18779444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BULLER, Christopher E</creatorcontrib><creatorcontrib>YULING FU</creatorcontrib><creatorcontrib>GRANGER, Christopher B</creatorcontrib><creatorcontrib>ARMSTRONG, Paul W</creatorcontrib><creatorcontrib>MAHAFFEY, Kenneth W</creatorcontrib><creatorcontrib>TODARO, Thomas G</creatorcontrib><creatorcontrib>ADAMS, Péter</creatorcontrib><creatorcontrib>WESTERHOUT, Cynthia M</creatorcontrib><creatorcontrib>WHITE, Harvey D</creatorcontrib><creatorcontrib>VAN 'T HOF, Arnoud W. J</creatorcontrib><creatorcontrib>VAN DE WERF, Frans J</creatorcontrib><creatorcontrib>WAGNER, Galen S</creatorcontrib><title>ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction.
We analyzed ECG data describing the magnitude and extent of ST-segment elevation and deviation before and early after (ie, 30 minutes) primary PCI in the study cohort of 4866 subjects with electrocardiographically high-risk ST-elevation myocardial infarction enrolled in the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Associations among 6 methods for calculating ST-segment recovery, biomarker estimates of infarct size (ie, peak creatine kinase, creatine kinase-MB, and troponin I and T), and prespecified clinical outcomes (ie, rates of 90-day death and 90-day death, heart failure, or shock) were examined. All ST-segment-recovery methods provided strong prognostic information regarding clinical outcomes. A simple ST-segment-recovery method of residual ST-segment elevation measurement in the most affected lead on the post-PCI ECG performed as well as complex methods that required comparison of pre- and post-PCI ECGs or calculation of summed ST-segment deviation in multiple leads (ie, worst-lead residual ST elevation: adjusted hazard ratio for 90-day death rate [reference <1 mm]: 1 to <2 mm, 1.23 [95% CI 0.74 to 2.03]; > or =2 mm, 2.22 [95% CI 1.35 to 3.65], corrected c-index=0.832; 90-day death/congestive heart failure/shock [reference <1 mm]: 1 to <2 mm, 1.55 [95% CI 1.06 to 2.26]; > or =2 mm, 2.33 [95% CI 1.59 to 3.41], corrected c-index=0.802). Biomarker estimates of infarct size declined in association with enhanced ST-segment recovery.
An ECG performed early after primary PCI is a simple, widely available, inexpensive, and powerful prognostic tool applicable to patients with ST-elevation myocardial infarction.</description><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary - mortality</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cohort Studies</subject><subject>Combined Modality Therapy</subject><subject>Coronary heart disease</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - therapy</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Recovery of Function</subject><subject>Shock, Cardiogenic - mortality</subject><subject>Single-Chain Antibodies</subject><subject>Treatment Outcome</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAQhi0EotvCKyBzAMEhS-w4sc0tirY00pZdtVuJW-Q44zYoiYudrFrek_fB3axAHDhZ888381vzI_SWxEtCMvKpKK-Km3W-Kzdf84t8SWKx5BnnnD5DC5JSFrE0kc_RIo5jGfGE0hN06v33UGYJT1-iEyI4l4yxBfp1vYuu4baHYcRXoO0e3CNWQ4M306htDzg3Izi8dW2vQmcLTk-jGsBOHhfW2eFJLYfA7MOK1g7YWIfD0lUHe3UQLh-tVq5pVRdAo5w-qJ9D4dvbu9Hjc2d7PN4FL-_B-8NfrAleD9C1P6de1bgdcB6M4T_LPuTb1bcovyw_4p0LvVfohVGdh9fH9wzdnK92xUW03nwpi3wd6SShY6RAmFgSImNeK90kCcRKKMNoraUWSnMDRjBKslQ2qmbMGEloLbkQXNGUZckZej_vvXf2xwR-rPrWa-i6-UJVJlMhmSABlDOonfXeganu54tWJK6eMq3-zTTIopozDbNvjiZT3UPzd_IYYgDeHQHlteqMU4Nu_R-OxpkkkmTJb5KssBk</recordid><startdate>20080923</startdate><enddate>20080923</enddate><creator>BULLER, Christopher E</creator><creator>YULING FU</creator><creator>GRANGER, Christopher B</creator><creator>ARMSTRONG, Paul W</creator><creator>MAHAFFEY, Kenneth W</creator><creator>TODARO, Thomas G</creator><creator>ADAMS, Péter</creator><creator>WESTERHOUT, Cynthia M</creator><creator>WHITE, Harvey D</creator><creator>VAN 'T HOF, Arnoud W. J</creator><creator>VAN DE WERF, Frans J</creator><creator>WAGNER, Galen S</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080923</creationdate><title>ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial</title><author>BULLER, Christopher E ; YULING FU ; GRANGER, Christopher B ; ARMSTRONG, Paul W ; MAHAFFEY, Kenneth W ; TODARO, Thomas G ; ADAMS, Péter ; WESTERHOUT, Cynthia M ; WHITE, Harvey D ; VAN 'T HOF, Arnoud W. J ; VAN DE WERF, Frans J ; WAGNER, Galen S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-ae8f0911907bacd33e0a8af42bc9c8ac7fef8421659dab44ff912b97887a25463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary - mortality</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cohort Studies</topic><topic>Combined Modality Therapy</topic><topic>Coronary heart disease</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - therapy</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Recovery of Function</topic><topic>Shock, Cardiogenic - mortality</topic><topic>Single-Chain Antibodies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BULLER, Christopher E</creatorcontrib><creatorcontrib>YULING FU</creatorcontrib><creatorcontrib>GRANGER, Christopher B</creatorcontrib><creatorcontrib>ARMSTRONG, Paul W</creatorcontrib><creatorcontrib>MAHAFFEY, Kenneth W</creatorcontrib><creatorcontrib>TODARO, Thomas G</creatorcontrib><creatorcontrib>ADAMS, Péter</creatorcontrib><creatorcontrib>WESTERHOUT, Cynthia M</creatorcontrib><creatorcontrib>WHITE, Harvey D</creatorcontrib><creatorcontrib>VAN 'T HOF, Arnoud W. J</creatorcontrib><creatorcontrib>VAN DE WERF, Frans J</creatorcontrib><creatorcontrib>WAGNER, Galen S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BULLER, Christopher E</au><au>YULING FU</au><au>GRANGER, Christopher B</au><au>ARMSTRONG, Paul W</au><au>MAHAFFEY, Kenneth W</au><au>TODARO, Thomas G</au><au>ADAMS, Péter</au><au>WESTERHOUT, Cynthia M</au><au>WHITE, Harvey D</au><au>VAN 'T HOF, Arnoud W. J</au><au>VAN DE WERF, Frans J</au><au>WAGNER, Galen S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2008-09-23</date><risdate>2008</risdate><volume>118</volume><issue>13</issue><spage>1335</spage><epage>1346</epage><pages>1335-1346</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction.
We analyzed ECG data describing the magnitude and extent of ST-segment elevation and deviation before and early after (ie, 30 minutes) primary PCI in the study cohort of 4866 subjects with electrocardiographically high-risk ST-elevation myocardial infarction enrolled in the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Associations among 6 methods for calculating ST-segment recovery, biomarker estimates of infarct size (ie, peak creatine kinase, creatine kinase-MB, and troponin I and T), and prespecified clinical outcomes (ie, rates of 90-day death and 90-day death, heart failure, or shock) were examined. All ST-segment-recovery methods provided strong prognostic information regarding clinical outcomes. A simple ST-segment-recovery method of residual ST-segment elevation measurement in the most affected lead on the post-PCI ECG performed as well as complex methods that required comparison of pre- and post-PCI ECGs or calculation of summed ST-segment deviation in multiple leads (ie, worst-lead residual ST elevation: adjusted hazard ratio for 90-day death rate [reference <1 mm]: 1 to <2 mm, 1.23 [95% CI 0.74 to 2.03]; > or =2 mm, 2.22 [95% CI 1.35 to 3.65], corrected c-index=0.832; 90-day death/congestive heart failure/shock [reference <1 mm]: 1 to <2 mm, 1.55 [95% CI 1.06 to 2.26]; > or =2 mm, 2.33 [95% CI 1.59 to 3.41], corrected c-index=0.802). Biomarker estimates of infarct size declined in association with enhanced ST-segment recovery.
An ECG performed early after primary PCI is a simple, widely available, inexpensive, and powerful prognostic tool applicable to patients with ST-elevation myocardial infarction.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>18779444</pmid><doi>10.1161/CIRCULATIONAHA.108.767772</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2008-09, Vol.118 (13), p.1335-1346 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69589481 |
| source | MEDLINE; American Heart Association Journals; EZB Electronic Journals Library; Journals@Ovid Complete |
| subjects | Aged Angioplasty, Balloon, Coronary - mortality Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cohort Studies Combined Modality Therapy Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Electrocardiography Female Heart Heart Failure - mortality Humans Kaplan-Meier Estimate Male Medical sciences Middle Aged Multivariate Analysis Myocardial Infarction - diagnosis Myocardial Infarction - mortality Myocardial Infarction - therapy Predictive Value of Tests Prognosis Recovery of Function Shock, Cardiogenic - mortality Single-Chain Antibodies Treatment Outcome |
| title | ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T17%3A59%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ST-Segment%20Recovery%20and%20Outcome%20After%20Primary%20Percutaneous%20Coronary%20Intervention%20for%20ST-Elevation%20Myocardial%20Infarction%20:%20Insights%20From%20the%20Assessment%20of%20Pexelizumab%20in%20Acute%20Myocardial%20Infarction%20(APEX-AMI)%20Trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=BULLER,%20Christopher%20E&rft.date=2008-09-23&rft.volume=118&rft.issue=13&rft.spage=1335&rft.epage=1346&rft.pages=1335-1346&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIRCULATIONAHA.108.767772&rft_dat=%3Cproquest_cross%3E69589481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69589481&rft_id=info:pmid/18779444&rfr_iscdi=true |